Difference between revisions of "Acute promyelocytic leukemia"
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
Warner-admin (talk | contribs) m (Text replacement - "#66FF66" to "#fee0d1") |
||
Line 12: | Line 12: | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: # | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> |
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
|} | |} |
Revision as of 03:50, 14 January 2018
Hello! |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
31 regimens on this page
48 variants on this page
|
Guidelines
ELN
- 2009: Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet PubMed
ESMO
- 2013: Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
Upfront induction therapy
Arsenic trioxide monotherapy
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Shen et al. 2004 | Randomized | Arsenic trioxide & ATRA | Seems to have inferior DFS |
ATRA | Not reported |
Chemotherapy
- Arsenic trioxide (Trisenox) 0.16 mg/kg IV once per day
Given until complete remission
Patients in CR proceeded to consolidation, see text for details.
Regimen #2
Study | Evidence |
---|---|
Mathews et al. 2006 | Non-randomized |
Chemotherapy
- Arsenic trioxide (Trisenox) 10 mg (0.15 mg/kg for pediatric patients) IV over 2 to 3 hours once per day
Given until complete remission (CR) or maximum of 75 days (maximum of 60 days after 2001)
Patients in CR proceed after 4 weeks to arsenic trioxide consolidation.
References
- Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24. link to original article contains verified protocol link to PMC article PubMed
- Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32. Epub 2005 Dec 13. link to original article contains verified protocol PubMed
- Update: Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P,Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010 Aug 20;28(24):3866-71. Epub 2010 Jul 19. link to original article PubMed
Arsenic trioxide & ATRA
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Burnett et al. 2015 (AML17) | Phase III | ATRA & Idarubicin | Seems not superior |
Chemotherapy
- Arsenic trioxide (Trisenox) 0.3 mg/kg IV once per day on days 1 to 5, then 0.25 mg/kg IV twice per week on weeks 2 to 8
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days
Treatment followed by arsenic trioxide & ATRA consolidation.
Regimen #2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Lo-Coco et al. 2013 (GIMEMA/DSIL APL0406) | Phase III | ATRA & Idarubicin | Superior OS (*) |
Patients with low- or intermediate-risk APL (white blood cell count at presentation less than or equal to 10 x 109/L) were eligible. Efficacy is based on the 2016 update.
Chemotherapy
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
Supportive medications
- Prednisone (Sterapred) 0.5 mg/kg PO once per day from days 1 until the end of induction or the onset of differentiation syndrome
- Patients who develop differentiation syndrome then received: Dexamethasone (Decadron) 10 mg IV every 12 hours until signs and symptoms resolve, and for a minimum of 3 days
- Hemostatic support: Transfusions to keep platelet count greater than 30 x 109/L for the first 10 days of induction and greater than 20 x 109/L for the remainder of induction
- Hydroxyurea (Hydrea) as follows:
- Patients with WBC count greater than 10 x 109/L and less than 50 x 109/L after the start of therapy received: 500 mg PO four times per day, given until WBC count is less than 10 x 109/L
- Patients with WBC count greater than 50 x 109/L after the start of therapy received: 1000 mg PO four times per day, given until WBC count is less than 10 x 109/L
One course, to remission
Treatment followed by arsenic trioxide & ATRA consolidation.
Regimen #3
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Shen et al. 2004 | Randomized | Arsenic trioxide ATRA |
Seems to have superior DFS |
Chemotherapy
- All-trans retinoic acid (ATRA) 25 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
- Arsenic trioxide (Trisenox) 0.16 mg/kg IV once per day, starting day 1 and continuing until remission
All patients achieving CR went on to receive chemotherapy-based consolidation and maintenance. These details are available in the original paper but are omitted here.
Regimen #4
Study | Evidence |
---|---|
Estey et al. 2006 | Phase II |
Ravandi et al. 2009 | Phase II |
The original protocol was modified between Estey et al. 2006 and Ravandi et al. 2009. Estey et al. 2006 covered part of the whole cohort. In the initial protocol, arsenic trioxide was started on day 11, and gemtuzumab ozogamicin was only used for high risk patients. After a death due to hyperleukocytosis and intracranial hemorrhage during induction, the protocol was modified as described in Ravandi et al. 2009 so arsenic trioxide was started on day 1, and gemtuzumab ozogamicin was given if WBC count went greater than 30 x 109/L for any patient in the first four weeks of therapy.
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until remission or maximum of 90 days.
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 60 minutes once per day, starting on day 11 and continuing until remission (as described in Estey et al. 2006)
- Patients in Ravandi et al. 2009 received 0.15 mg/kg IV over 60 minutes once per day, starting on day 1 and continuing until remission
- Patients with high-risk disease (initial WBC count greater than or equal to 10 x 109/L) received: Gemtuzumab ozogamicin (Mylotarg) 9 mg/m2 IV once on day 1
- Patients who initially were not high-risk but subsequently developed WBC count greater than or equal to 10 x 109/L during the first four weeks of therapy received: 9 mg/m2 IV once
Supportive medications
- "Prophylactic and therapeutic antibiotics and transfusion of blood products to maintain platelet counts more than 30 x 109/L, fibrinogen more than 150 mg/dL, and the international normalized ratio for prothrombin time less than 1.5" per institutional guidelines
- Heparin or Tranexamic acid (Cyklokapron) used if clinically indicated
- Patients in Estey et al. 2006 received: "Oral solumedrol" 20 mg PO once per day for 10 days to decrease risk of differentiation syndrome
- Patients in Ravandi et al. 2009 recieved: Methylprednisolone 50 mg PO once per day for 5 days to decrease risk of differentiation syndrome
Treatment followed by arsenic trioxide & ATRA consolidation.
References
- Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24. link to original article contains verified protocol link to PMC article PubMed
- Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 1;107(9):3469-73. Epub 2005 Dec 22. link to original article contains verified protocol PubMed
- Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 1;27(4):504-10. Epub 2008 Dec 15. link to original article contains verified protocol link to PMC article PubMed
- Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. Epub 2009 Feb 18. link to original article contains verified protocol link to PMC article PubMed content property of HemOnc.org
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. link to original article link to supplementary appendix link to protocol contains verified protocol PubMed
- Update: Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. Epub 2016 Oct 31. link to original article link to PMC article PubMed
- Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305. Epub 2015 Sep 14. link to SD article contains protocol PubMed
Arsenic trioxide, ATRA, Idarubicin
back to top |
Regimen
Study | Evidence |
---|---|
Iland et al. 2012 (APML4) | Phase II |
Chemotherapy
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 2 hours once per day on days 9 to 36
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 36
- Idarubicin (Idamycin) as follows:
- Patients up to age 61: 12 mg/m2 IV once per day on days 2, 4, 6, 8
- Patients 61 to 70 years old: 9 mg/m2 IV once per day on days 2, 4, 6, 8
- Patients greater than 70 years old: 6 mg/m2 IV once per day on days 2, 4, 6, 8
Supportive medications
- Prednisone (Sterapred) 1 mg/kg PO once per day on days 1 to 10, or until WBC count falls below 1 x 109/L, or until resolution of differentiation syndrome (whichever occurs last)
- Hemostatic support : Values checked and products transfused once or twice per day to keep platelet count greater than 30 x 109/L, fibrinogen greater than 1.5 g/L (150 mg/dL), normal PT and PTT
- Electrolyte support while on Arsenic trioxide (Trisenox): supplemental potassium and magnesium given to keep levels in the upper half of their normal ranges
36-day course
Treatment followed in 3 to 4 weeks by arsenic trioxide & ATRA consolidation.
References
- Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed
ATRA monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Tallman et al. 1997 (ECOG E2491) | Phase III | Cytarabine & Daunorubicin | Superior OS |
This obsolete regimen is here for historical reference; ATRA is no longer used as monotherapy for induction.
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
Treatment followed by ATRA consolidation, then cytarabine & daunorubicin consolidation.
References
- Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 Oct 9;337(15):1021-8. Erratum in: N Engl J Med 1997 Nov 27;337(22):1639. link to original article contains verified protocol PubMed
ATRA, Cytarabine, Daunorubicin
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Adès et al. 2006 (APL 2000) | Phase III | ATRA & Daunorubicin | Superior OS |
This induction arm was a randomization for young (less than 60), low-risk (WBC count less than 10 x 109/L) patients. High-risk (WBC count greater than 10 x 109/L) patients received this regimen in a non-randomized fashion, along with intrathecal therapy during consolidation.
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
- Cytarabine (Cytosar) 200 mg/m2 IV continuous infusion on days 3 to 9
- Daunorubicin (Cerubidine) 60 mg/m2 IV once per day on days 3 to 5
9-day course of initial induction chemotherapy, with ongoing use of ATRA
Treatment followed by cytarabine & daunorubicin consolidation.
Regimen #2
Study | Evidence |
---|---|
Powell et al. 2010 (C9710) | Non-randomized portion of RCT |
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 3 to 9
- Daunorubicin (Cerubidine) 50 mg/m2 IV once per day on days 3 to 6
9-day initial induction chemotherapy, with ongoing use of ATRA
Treatment followed by randomization to arsenic trioxide, then ATRA & daunorubicin consolidation versus ATRA & daunorubicin consolidation.
References
- Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993 Dec 1;82(11):3241-9. link to original article PubMed
- Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol link to PMC article PubMed
ATRA & Daunorubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Adès et al. 2006 (APL 2000) | Phase III | ATRA, Cytarabine, Daunorubicin | Inferior OS |
This induction arm was a randomization for young (less than 60), low-risk (WBC count less than 10 x 109/L) patients. Low-risk (WBC count less than 10 x 109/L) older (greater than 60) patients received this regimen in a non-randomized fashion.
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
- Daunorubicin (Cerubidine) 60 mg/m2 IV once per day on days 3 to 5
9-day course of initial induction chemotherapy, with ongoing use of ATRA
Treatment followed by daunorubicin consolidation.
References
- Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
ATRA & Idarubicin
back to top |
AIDA: ATRA, IDArubicin
PETHEMA: Programa Español de Tratamientos en HEMAtología
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Avvisati et al. 1996 | Pilot | ||
Mandelli et al. 1997 (AIDA 0493) | Non-randomized portion of RCT | ||
Sanz et al. 2004 (PETHEMA LPA96/LPA99) | Non-randomized | ||
Sanz et al. 2010 (PETHEMA LPA2005) | Non-randomized | ||
Lo-Coco et al. 2010 (AIDA 2000) | Non-randomized | ||
Latagliata et al. 2011 (AIDA 0493 amended protocol) | Non-randomized | ||
Lo-Coco et al. 2013 (GIMEMA/DSIL APL0406) | Phase III | Arsenic trioxide & ATRA | Inferior OS (*) |
Burnett et al. 2015 (NCRI AML17) | Phase III | Arsenic trioxide & ATRA | Seems not superior |
Note: this is the same induction used in multiple protocols. Consolidation and maintenance differ, follow the appropriate links below. Efficacy in APL0406 is based on the 2016 update.
Chemotherapy
- All-trans retinoic acid (ATRA) as follows, starting day 1 and continuing until remission or maximum of 90 days:
- 21 or older: 45 mg/m2/day, divided into two equal doses PO BID
- Less than 20 years old: 25 mg/m2/day, divided into two equal doses PO BID
- Idarubicin (Idamycin) as follows:
- Up to age 70: 12 mg/m2 IV bolus once per day on days 2, 4, 6, 8
- Older than 70 years old: 12 mg/m2 IV bolus once per day on days 2, 4, 6
8-day initial induction chemotherapy, with ongoing use of ATRA as described
Once CR was achieved, patients proceeded to consolidation as follows:
- Patients in PETHEMA LPA96 proceeded to receive idarubicin, then mitoxantrone, then idarubicin consolidation.
- Patients in AIDA 0493 proceeded to receive cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine consolidation.
- Patients in PETHEMA LPA99 proceeded to receive risk-adapted therapy:
- Low-risk patients received idarubicin, then mitoxantrone, then idarubicin consolidation.
- Intermediate- and high-risk patients received idarubicin, then mitoxantrone, then idarubicin, with ATRA consolidation.
- Patients in PETHEMA LPA2005 proceeded to receive risk-adapted therapy:
- High-risk patients received cytarabine & idarubicin, then mitoxantrone, then cytarabine & idarubicin, with ATRA consolidation.
- Intermediate- and low-risk patients received idarubicin, then mitoxantrone, then idarubicin, with ATRA consolidation.
- Patients in AIDA 2000 proceeded to receive risk-adapted therapy:
- High-risk patients received cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine, with ATRA consolidation.
- Intermediate- and low-risk patients received idarubicin, then mitoxantrone, then idarubicin, with ATRA consolidation.
- Patients in the AIDA 0493 amended protocol proceeded to receive cytarabine & idarubicin consolidation.
- Patients in GIMEMA/DSIL APL0406 and NCRI AML17 proceeded to receive idarubicin, then mitoxantrone, then idarubicin, with ATRA consolidation.
References
- Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996 Aug 15;88(4):1390-8. link to full article contains verified protocol PubMed
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
- Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed
- Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. Epub 2011 Jul 14. link to full article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. link to original article contains verified protocol PubMed
- Update: Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. Epub 2016 Oct 31. link to original article link to PMC article PubMed
- Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305. Epub 2015 Sep 14. link to original article PubMed
Consolidation after upfront therapy
Arsenic trioxide monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Mathews et al. 2006 | Non-randomized |
Preceding treatment
Chemotherapy
- Arsenic trioxide (Trisenox) 10 mg (0.15 mg/kg for pediatric patients) IV over 2 to 3 hours once per day
28-day course
Patients remaining in CR proceed to arsenic trioxide maintenance.
References
- Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32. Epub 2005 Dec 13. link to original article contains verified protocol PubMed
- Update: Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P,Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010 Aug 20;28(24):3866-71. Epub 2010 Jul 19. link to original article PubMed
Arsenic trioxide, then ATRA & Daunorubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Powell et al. 2010 (C9710) | Phase III | ATRA & Daunorubicin | Superior EFS |
Consolidation therapy starts within 2 to 4 weeks of hematologic remission.
Preceding treatment
Chemotherapy, part 1
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV once per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33
7-week cycles (5 weeks of therapy, then 2 weeks off), followed by:
Chemotherapy, part 2
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting days 1 to 7
- Daunorubicin (Cerubidine) 50 mg/m2 IV once per day on days 1 to 3
7-day cycle for 2 cycles
Treatment followed by ATRA maintenance versus ATRA, 6-MP, MTX maintenance.
References
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol link to PMC article PubMed
Arsenic trioxide & ATRA
back to top |
Regimen #1
Study | Evidence |
---|---|
Estey et al. 2006 | Phase II |
Lo-Coco et al. 2013 (GIMEMA/DSIL APL0406) | Non-randomized portion of RCT |
Preceding treatment
Chemotherapy
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 1 to 2 hours once per day, 5 consecutive days per week, on weeks 1 to 4, 9 to 12, 17 to 20, 25 to 28
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, 7 days per week on weeks 1 to 2, 5 to 6, 9 to 10, 13 to 14, 17 to 18, 21 to 22, 25 to 26
28 week course of therapy
There is no maintenance in this protocol.
Regimen #2
Study | Evidence |
---|---|
Iland et al. 2012 (APML4) | Phase II |
Consolidation starts 3 to 4 weeks after completion of induction.
Preceding treatment
Chemotherapy, part 1
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 28
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV once per day on days 1 to 28
4-week course; after 3 to 4 weeks, proceed to consolidation cycle 2
Chemotherapy, part 2
Given 3 to 4 weeks after completion of consolidation cycle 1.
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 7, 15 to 21, 29 to 35
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV once per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33
5-week course
After 3 to 4 weeks, patients proceed to ATRA, 6-MP, MTX maintenance.
References
- Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 1;107(9):3469-73. Epub 2005 Dec 22. link to original article contains verified protocol PubMed
- Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. link to original article link to supplementary appendix link to protocol contains verified protocol PubMed
- Update: Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. Epub 2016 Oct 31. link to original article link to PMC article PubMed
- Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305. Epub 2015 Sep 14. link to SD article PubMed
ATRA & Daunorubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Powell et al. 2010 (C9710) | Phase III | Arsenic trioxide, then ATRA & Daunorubicin | Inferior EFS |
Consolidation therapy starts within 2 to 4 weeks of hematologic remission.
Preceding treatment
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting days 1 to 7
- Daunorubicin (Cerubidine) 50 mg/m2 IV once per day on days 1 to 3
7-day cycle for 2 cycles
Treatment followed by randomization to ATRA maintenance versus ATRA, 6-MP, MTX maintenance.
References
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol link to PMC article PubMed
Cytarabine & Daunorubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Adès et al. 2006 (APL 2000) | Phase III | Daunorubicin | Superior OS |
Preceding treatment
Chemotherapy
- Cytarabine (Cytosar) as follows:
- Cycle 1: 200 mg/m2/day IV continuous infusion on days 1 to 7
- Cycle 2 as follows:
- Younger (less than 60) low-risk (WBC count less than 10 x 109/L) or older (greater than 60) high-risk (WBC count greater than 10 x 109/L): 1000 mg/m2 IV every 12 hours on days 1 to 4 (8 total doses)
- Younger (less than 60) high-risk (WBC count greater than 10 x 109/L): 2000 mg/m2 IV every 12 hours on days 1 to 5 (10 total doses)
- Daunorubicin (Cerubidine) as follows:
- Cycle 1: 60 mg/m2 IV once per day on days 1 to 3
- Cycle 2: 45 mg/m2 IV once per day on days 1 to 3
Intrathecal for high-risk (WBC count greater than 10 x 109/L) patients
- 5 doses of intrathecal chemotherapy with Methotrexate (MTX) 15 mg IT, Cytarabine (Cytosar) 50 mg IT, and corticosteroids given during consolidation
Treatment followed by ATRA, 6-MP, MTX maintenance.
References
- Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
Cytarabine & Idarubicin
back to top |
Regimen
Study | Evidence |
---|---|
Latagliata et al. 2011 (AIDA 0493 amended protocol) | Non-randomized |
This consolidation protocol was intended for patients older than 60.
Preceding treatment
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV over 6 hours once per day on days 1 to 4, given first
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4, given second, 3 hours after cytarabine infusion complete
One course
Treatment is followed by ATRA maintenance.
References
- Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. Epub 2011 Jul 14. link to full article contains verified protocol PubMed
Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine
back to top |
Regimen
Study | Evidence |
---|---|
Mandelli et al. 1997 (AIDA 0493) | Non-randomized portion of RCT |
Avvisati et al. 2002 (LAP 0389) | Non-randomized portion of RCT |
Note that the consolidation portion of the AIDA 0493 protocol is described in Avvisati et al. 1996.
Preceding treatment
- LAP 0389: Idarubicin induction versus cytarabine & idarubicin induction (neither with ATRA; no longer standard of care)
- AIDA 0493: ATRA & idarubicin induction
Chemotherapy, part 1
- Cytarabine (Cytosar) 1000 mg/m2 IV over 6 hours once per day on days 1 to 4, given first
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4, given second, 3 hours after cytarabine infusion complete
One course
Next course to begin "at recovery from the previous one, when polymorphonuclear cells numbered 1500/uL or more and platelets numbered 100 x 109/L or more."
Chemotherapy, part 2
- Etoposide (Vepesid) 100 mg/m2 IV over 45 to 60 minutes oncer per day on days 1 to 5, given second, 12 hours after start of mitoxantrone
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 5, given first
One course
Next course to begin "at recovery from the previous one, when polymorphonuclear cells numbered 1500/uL or more and platelets numbered 100 x 109/L or more."
Chemotherapy, part 3
- Cytarabine (Cytosar) 150 mg/m2 SC every 8 hours on days 1 to 5
- Idarubicin (Idamycin) as follows:
- LAP 0389 protocol: 5 mg/m2 IV once on day 1
- AIDA 0493 protocol: 12 mg/m2 IV once on day 1
- Thioguanine (Tabloid) 70 mg/m2 PO every 8 hours on days 1 to 5
One course
Treatment in LAP 0389 followed by 6-MP & MTX maintenance versus no further treatment. Treatment in AIDA 0493 followed by ATRA maintenance versus ATRA, 6-MP, MTX maintenance versus 6-MP & MTX maintenance versus no further treatment.
References
- Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996 Aug 15;88(4):1390-8. link to full article contains verified protocol PubMed
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains verified protocol PubMed
Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA
back to top |
AIDA: ATRA, IDArubicin
Regimen
Study | Evidence |
---|---|
Lo-Coco et al. 2010 (AIDA-2000) | Non-randomized |
This is risk-adapted therapy for high-risk patients in AIDA-2000. The authors were unclear about how many days were between each part of consolidation therapy.
Preceding treatment
Chemotherapy, part 1
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Cytarabine (Cytosar) 1000 mg/m2 IV once per day on days 1 to 4
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4
4-day course of therapy, followed by:
Chemotherapy, part 2
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 5
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 5
5-day course of therapy, followed by:
Chemotherapy, part 3
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Cytarabine (Cytosar) 150 mg/m2 SC every 8 hours (450 mg/m2/day total dosage) on days 1 to 5
- Idarubicin (Idamycin) 12 mg/m2 IV once on day 1
- Thioguanine (Tabloid) 70 mg/m2 PO every 8 hours (210 mg/m2/day total dosage) on days 1 to 5
5-day course of therapy
CNS prophylaxis
It is not explicitly stated but presumably these are admixed and given together.
- Methotrexate (MTX) 12 mg IT once prior to each consolidation cycle
- Methylprednisolone (Solumedrol) 40 mg IT once prior to each consolidation cycle
"Total of 3 cycles"
Treatment followed by ATRA alternating with 6-MP, MTX maintenance.
References
- Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed
Cytarabine & Idarubicin, then Mitoxantrone, then Cytarabine & Idarubicin, with ATRA
back to top |
PETHEMA: Programa Español de Tratamientos en HEMAtología
Regimen
Study | Evidence |
---|---|
Sanz et al. 2010 (PETHEMA LPA2005) | Non-randomized |
This is risk-adapted therapy for high-risk younger than 60 patients in PETHEMA LPA2005. Note that it is unclear from the paper which route the cytarabine is given in the third consolidation; this dose can be given by IV or SC routes.
Preceding treatment
Chemotherapy, consolidation #1
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4
- Cytarabine (Cytosar) 1000 mg/m2 IV once per day on days 1 to 4
1-month cycle, followed by:
Chemotherapy, consolidation #2
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 5
1-month cycle, followed by:
Chemotherapy, consolidation #3
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Idarubicin (Idamycin) 12 mg/m2 IV once on day 1
- Cytarabine (Cytosar) 150 mg/m2, IV/SC every 8 hours (total dose of 450 mg/m2/day) on days 1 to 4 (12 total doses)
1-month cycle
Treatment followed by ATRA, 6-MP, MTX maintenance.
References
- Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed
Daunorubicin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Adès et al. 2006 (APL 2000) | Phase III | Cytarabine & Daunorubicin | Inferior OS |
This consolidation arm was a randomization for younger (less than 60), low-risk (WBC count less than 10 x 109/L) patients. Low-risk (WBC count less than 10 x 109/L) older (greater than 60) patients received this regimen in a non-randomized fashion.
Preceding treatment
Chemotherapy
- Daunorubicin (Cerubidine) as follows:
- Cycle 1: 60 mg/m2 IV once per day on days 1 to 3
- Cycle 2: 45 mg/m2 IV once per day on days 1 to 3
Treatment followed by ATRA, 6-MP, MTX maintenance.
References
- Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
Idarubicin, then Mitoxantrone, then Idarubicin
back to top |
PETHEMA: Programa Español de Tratamientos en HEMAtología
Regimen
Study | Evidence |
---|---|
Sanz et al. 2004 (PETHEMA LPA96/LPA99) | Non-randomized |
This was the low-risk treatment arm of PETHEMA LPA99; all patients on PETHEMA LPA96 underwent this consolidation protocol.
Preceding treatment
Chemotherapy, part 1
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4
1-month cycle, followed by:
Chemotherapy, part 2
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 5
1-month cycle, followed by:
Chemotherapy, part 3
- Idarubicin (Idamycin) 12 mg/m2 IV once on day 1
1-month cycle
Treatment followed by ATRA, 6-MP, MTX maintenance.
References
- Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA
back to top |
AIDA: ATRA, IDArubicin
PETHEMA: Programa Español de Tratamientos en HEMAtología
Regimen #1
Study | Evidence |
---|---|
Lo-Coco et al. 2010 (AIDA-2000) | Non-randomized |
Sanz et al. 2010 (PETHEMA LPA2005) | Non-randomized |
Lo-Coco et al. 2013 (GIMEMA/DSIL APL0406) | Non-randomized portion of RCT |
This is risk-adapted therapy for intermediate- and low-risk patients in AIDA-2000 and for low-risk patients in PETHEMA LPA2005; all patients assigned to the chemotherapy arm of GIMEMA/DSIL APL0406 received this treatment. Note that the number of mitoxantrone doses differs between the protocols.
Preceding treatment
Chemotherapy, part 1
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Idarubicin (Idamycin) 5 mg/m2 IV once per day on days 1 to 4
1-month cycle, followed by:
Chemotherapy, part 2
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Mitoxantrone (Novantrone) as follows:
- AIDA-2000 & GIMEMA/DSIL APL0406: 10 mg/m2 IV once per day on days 1 to 5
- PETHEMA LPA2005: 10 mg/m2 IV once per day on days 1 to 3
1-month cycle, followed by:
Chemotherapy, part 3
- All-trans retinoic acid (ATRA) 45 mg/m2/day PO for a total of 15 days
- Idarubicin (Idamycin) 12 mg/m2 IV once on day 1
1-month cycle
Treatment in AIDA-2000 and GIMEMA/DSIL APL0406 followed by ATRA alternating with 6-MP, MTX maintenance. Treatment in PETHEMA LPA2005 followed by ATRA, 6-MP, MTX maintenance.
Regimen #2
Study | Evidence |
---|---|
Sanz et al. 2003 (PETHEMA LPA99) | Non-randomized |
Sanz et al. 2010 (PETHEMA LPA2005) | Non-randomized |
This is risk-adapted therapy for intermediate- and high-risk patients in PETHEMA LPA99 and for intermediate-risk and high-risk older than 60 patients in PETHEMA LPA2005. Note that the number of mitoxantrone doses differs between the two protocols.
Preceding treatment
Chemotherapy, part 1
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Idarubicin (Idamycin) 7 mg/m2 IV once per day on days 1 to 4
1-month cycle, followed by:
Chemotherapy, part 2
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Mitoxantrone (Novantrone) as follows:
- PETHEMA LPA99: 10 mg/m2 IV once per day on days 1 to 5
- PETHEMA LPA2005: 10 mg/m2 IV once per day on days 1 to 3
1-month cycle, followed by:
Chemotherapy, part 3
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1 to 15
- Idarubicin (Idamycin) 12 mg/m2 IV once per day on days 1 & 2
1-month cycle
Treatment followed by ATRA, 6-MP, MTX maintenance.
References
- Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
- Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. link to original article contains verified protocol PubMed
- Update: Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. Epub 2016 Oct 31. link to original article link to PMC article PubMed
Maintenance after upfront therapy
Arsenic trioxide monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Mathews et al. 2006 | Non-randomized |
====Preceding treatment==== *Arsenic trioxide consolidation
Chemotherapy
- Arsenic trioxide (Trisenox) 10 mg (0.15 mg/kg for pediatric patients) IV over 2 to 3 hours once per day
10 consecutive days of each month for 6 months
References
- Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32. Epub 2005 Dec 13. link to original article contains verified protocol PubMed
- Update: Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P,Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010 Aug 20;28(24):3866-71. Epub 2010 Jul 19. link to original article PubMed
ATRA monotherapy
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Powell et al. 2010 (C9710) | Phase III | ATRA, 6-MP, MTX | Might have inferior DFS |
Maintenance therapy starts 2 to 4 weeks after recovery from consolidation therapy.
Preceding treatment
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID for 7 days every other week
1 year of therapy
Regimen #2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Mandelli et al. 1997 (AIDA 0493) | Phase III | ATRA, 6-MP, MTX | Seems not superior |
6-MP & MTX | Seems not superior | ||
No further treatment | Seems not superior | ||
Fenaux et al. 1999 (APL93) | Phase III | ATRA, 6-MP, MTX | Inferior 2-year relapse rate |
6-MP & MTX No further treatment |
Seems to have superior 2-year relapse rate |
Preceding treatment
- AIDA 0493: Cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine consolidation
- APL 93: Cytarabine & daunorubicin consolidation
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day for 15 days every 3 months
2 year course of therapy
References
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200. link to original article PubMed
- Update: Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010 Mar 4;115(9):1690-6. Epub 2009 Dec 17. link to original article PubMed
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol link to PMC article PubMed
ATRA, Mercaptopurine, Methotrexate
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Powell et al. 2010 (C9710) | Phase III | ATRA | Might have superior DFS |
Maintenance therapy starts 2 to 4 weeks after recovery from consolidation therapy.
Preceding treatment
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID for 7 days every other week
- Mercaptopurine (Purinethol) 60 mg/m2 PO once per day
- Methotrexate (MTX) 20 mg/m2 PO once per week
1 year of therapy
Regimen #2
Study | Evidence |
---|---|
Adès et al. 2006 (APL 2000) | Non-randomized portion of RCT |
Preceding treatment
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 15
- Mercaptopurine (Purinethol) 50 to 90 mg/m2 PO once per day
- Methotrexate (MTX) 15 mg/m2 PO once per week
90-day cycle for 2 years
Regimen #3
Study | Evidence |
---|---|
Iland et al. 2012 (APML4) | Phase II |
Maintenance starts 3 to 4 weeks after completion of consolidation cycle 2.
Preceding treatment
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 14
- Mercaptopurine (Purinethol) 50 to 90 mg/m2 PO once per day on days 15 to 90
- Methotrexate (MTX) 5 to 15 mg/m2/week PO on days 15 to 90
Dose adjustments
- Methotrexate (MTX) and Mercaptopurine (Purinethol) doses titrated to ANC 1000 to 2000/uL and minimizing hepatotoxicity
90-day cycle for 8 cycles
Regimen #4
Study | Evidence |
---|---|
Sanz et al. 2003 (PETHEMA LPA99) | Non-randomized |
Sanz et al. 2010 (PETHEMA LPA2005) | Non-randomized |
Preceding treatment
- PETHEMA LPA99, low-risk: Idarubicin, then Mitoxantrone, then Idarubicin consolidation
- PETHEMA LPA99, intermediate- and high-risk and PETHEMA LPA2005, low- and intermediate-risk Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA consolidation
- PETHEMA LPA2005, high-risk: Cytarabine & Idarubicin, then Mitoxantrone, then Cytarabine & Idarubicin, with ATRA consolidation
Chemotherapy
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 15
- Mercaptopurine (Purinethol) 50 mg/m2 PO once per day
- Methotrexate (MTX) 15 mg/m2 IM once per week
Dose adjustments:
- Methotrexate (MTX) and Mercaptopurine (Purinethol) decreased by 50% if WBC count less than 3.5 × 109/L
- Methotrexate (MTX) and Mercaptopurine (Purinethol) stopped if WBC count less than 2.5 × 109/L
90-day cycle for 2 years
Regimen #5, ATRA alternating with 6-MP, MTX
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Mandelli et al. 1997 (AIDA 0493) | Phase III | ATRA | Seems not superior |
6-MP & MTX | Seems not superior | ||
No further treatment | Seems not superior | ||
Fenaux et al. 1999 (APL93) | Phase III | 6-MP & MTX | Seems to have superior 2-year relapse rate |
ATRA No further treatment |
Superior 2-year relapse rate |
Preceding treatment
- AIDA 0493: Cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine consolidation
- APL 93: Cytarabine & daunorubicin consolidation
Chemotherapy
- Mercaptopurine (Purinethol) 90 mg/m2 PO once per day
- Methotrexate (MTX) 15 mg/m2 IM once per week
3-month cycle, alternating with
- All-trans retinoic acid (ATRA) 45 mg/m2/day for 15 days
2 year course of therapy
References
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200. link to original article PubMed
- Update: Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010 Mar 4;115(9):1690-6. Epub 2009 Dec 17. link to original article PubMed
- Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
- Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
- Update: Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed
- Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article PubMed
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol link to PMC article PubMed
- Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. link to original article contains verified protocol PubMed
Mercaptopurine & Methotrexate
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Avvisati et al. 2002 (LAP 0389) | Phase III | No further treatment | Seems not superior |
Preceding treatment
Chemotherapy
- Mercaptopurine (Purinethol) 1 mg/kg PO once per day
- Methotrexate (MTX) 0.25 mg/kg IM once per week
2-year course of therapy
Regimen #2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Mandelli et al. 1997 (AIDA 0493) | Phase III | ATRA | Seems not superior |
ATRA, 6-MP, MTX | Seems not superior | ||
No further treatment | Seems not superior | ||
Fenaux et al. 1999 (APL93) | Phase III | ATRA ATRA, 6-MP, MTX |
Seems to have inferior 2-year relapse rate |
No further treatment | Superior 2-year relapse rate |
Note that this arm was dropped from AIDA 0493 from February 1997.
Preceding treatment
- AIDA 0493: Cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine consolidation
- APL 93: Cytarabine & daunorubicin consolidation
Chemotherapy
- Mercaptopurine (Purinethol) 90 mg/m2 PO once per day
- Methotrexate (MTX) 15 mg/m2 IM once per week
2-year course of therapy
References
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200. link to original article PubMed
- Update: Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010 Mar 4;115(9):1690-6. Epub 2009 Dec 17. link to original article PubMed
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains verified protocol PubMed
No further treatment
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Mandelli et al. 1997 (AIDA 0493) | Phase III | ATRA | Seems not superior |
ATRA, 6-MP, MTX | Seems not superior | ||
6-MP & MTX | Seems not superior | ||
Fenaux et al. 1999 (APL93) | Phase III | ATRA | Seems to have inferior 2-year relapse rate |
ATRA, 6-MP, MTX 6-MP & MTX |
Inferior 2-year relapse rate | ||
Avvisati et al. 2002 (LAP 0389) | Phase III | 6-MP & MTX | Seems not superior |
Preceded by Cytarabine & daunorubicin consolidation in APL 93. Preceded by Cytarabine & idarubicin, then etoposide & mitoxantrone, then cytarabine, idarubicin, thioguanine consolidation in AIDA 0493 and LAP 0389. No further treatment given after consolidation. Note that this arm was dropped from AIDA 0493 from February 1997.
References
- Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 Aug 1;90(3):1014-21. link to original article contains partial protocol PubMed
- Update: Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
- Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200. link to original article PubMed
- Update: Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010 Mar 4;115(9):1690-6. Epub 2009 Dec 17. link to original article PubMed
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains verified protocol PubMed
Relapsed or refractory, salvage therapy
Arsenic trioxide monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Shen et al. 1997 | Non-randomized, <20 pts |
Chemotherapy
- Arsenic trioxide (Trisenox) 10 mg IV over 2 to 3 hours once per day
Given until complete remission (CR)
Patients in CR proceed after 30 days to another 28-day course of arsenic trioxide.
References
- Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997 May 1;89(9):3354-60. link to original article PubMed
- Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998 Nov 5;339(19):1341-8. link to original article PubMed
- Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15;19(18):3852-60. link to original article PubMed
Arsenic-based re-induction followed by consolidation and autologous stem cell transplant
back to top |
Regimen
Study | Evidence |
---|---|
Yanada et al. 2013 | Phase II |
Induction
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days
- Idarubicin (Idamycin) 12 mg/m2 IV over 30 minutes once per day on days 1 & 2 (Idarubicin was added under special conditions; see text for details)
- Intrathecal therapy given once after platelet recovery, consisting of:
- Methotrexate (MTX) 15 mg IT,
- Cytarabine (Cytosar) 40 mg IT, and
- Corticosteroids: (Prednisolone (Millipred) 10 mg IT or Dexamethasone (Decadron) 4 mg IT
Consolidation #1 and #2
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days
- Intrathecal therapy given once after platelet recovery, consisting of:
- Methotrexate (MTX) 15 mg IT,
- Cytarabine (Cytosar) 40 mg IT, and
- Corticosteroids: (Prednisolone (Millipred) 10 mg IT or Dexamethasone (Decadron) 4 mg IT
Consolidation #3
- Cytarabine (Cytosar) 2 g/m2 IV over 3 hours twice per day on days 1 to 4 (8 doses total)
- Filgrastim (Neupogen) starting on day 6 (dose, frequency not specified)
Peripheral blood stem cells collected upon WBC count recovery, followed by:
- Busulfan (Myleran) & Melphalan (Alkeran), then autologous stem cell transplant; see transplant conditioning regimens
References
- Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. link to original article contains verified protocol PubMed